Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial
Authors
Keywords
-
Journal
Trials
Volume 23, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-23
DOI
10.1186/s13063-022-06356-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The JAK1 Selective Inhibitor ABT 317 Blocks Signaling Through Interferon-γ and Common γ Chain Cytokine Receptors to Reverse Autoimmune Diabetes in NOD Mice
- (2020) Tingting Ge et al. Frontiers in Immunology
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- (2020) William Damsky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Baricitinib for systemic lupus erythematosus – Authors' reply
- (2019) Daniel J Wallace et al. LANCET
- Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
- (2019) Charalampia Papadopoulou et al. BRAIN
- Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
- (2019) Anniina T. Virtanen et al. BIODRUGS
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables
- (2018) John M. Wentworth et al. DIABETOLOGIA
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response
- (2017) Matthew Clark et al. Frontiers in Immunology
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A model-based approach to sample size estimation in recent onset type 1 diabetes
- (2016) Brian N. Bundy et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases
- (2015) Yun R Li et al. NATURE MEDICINE
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- (2015) Ali Jabbari et al. EBioMedicine
- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
- (2014) Edward C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Proinflammatory cytokines contribute to development and function of regulatory T cells in type 1 diabetes
- (2012) Helen E. Thomas et al. Annals of the New York Academy of Sciences
- Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
- (2012) C. J. Greenbaum et al. DIABETES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now